A drug originally used to boost the immune system is showing promise as a potential new treatment for lupus, joint Monash University and Peking University research published today shows. Lupus is an autoimmune disease, where the immune system attacks the body’s own organs and tissues.
An international team of scientists from Australia and China have, for the first time, shown in a study published in Nature Medicine, that a natural immune system protein called IL-2 can help restore balance to the overactive immune system of lupus patients. The drug could soon be rolled out for clinical trials in lupus treatment.
Monash Biomedicine Discovery Institute researcher, Dr Di Yu and Professor Zhanguo Li from Peking University People’s Hospital in China co-led the study.
Dr Yu said he hoped the drug could be approved as a lupus treatment within a handful of years.
“This drug, which can help the immune system fight against cancer, was approved in the 1990s but is not commonly used now. We’re now using this drug for a different purpose, based on our new knowledge of the immune system,” Dr Yu said.
“The amount we tested for treating lupus is much less than the dose used in treating cancers. We observed the treatment was safe and showed promising results, so there’s reason to believe formal trials could begin almost immediately,” he said.
Dr Yu said lupus could be a serious disease, and that it hadn’t been able to be treated in a very satisfactory way in the past.
IL-2 is a protein that regulates the activity of white blood cells, which are an important part of the immune system that protect the body against infections. In cancer therapy, patients are given large doses of IL-2 to stimulate their immune system but, paradoxically, the low dose IL-2 given to lupus sufferers in this study actually supressed the overactive part of their immune system that attacks their body. The research also showed the “self-checking” part of the immune system that prevents an overactive immune response, called regulatory T cells, increased after IL-2 treatment.
Professor Eric Morand, fellow Monash University researcher on the study and founder of the Asia Pacific Lupus Collaboration, said that in this study, IL-2 was given to people whose lupus wasn’t responding well to standard treatments.
“The real promise of this treatment is that it calms the hyperactive immune system through multiple mechanisms, which is very important as this new therapy may be effective for many patients,” Professor Morand said.
”As the drug has been on the market for some time for other diseases, it can be rapidly put into formal trials for lupus treatment right away.”
Learn more: Promising new treatment for lupus on the horizon
The Latest on: Lupus
via Google News
The Latest on: Lupus
- Lupus patient in Oakland denied medication due to drug shortageon March 30, 2020 at 10:35 pm
Drugs now being used to treat coronavirus are becoming difficult for people with other health issues to obtain.
- NKF 2020: New Lupus Tx; Staying on Spironolactone, and Moreon March 30, 2020 at 2:30 pm
Novel Immunosuppressant for Lupus Nephritis Almost double the amount of people with active lupus nephritis saw a renal response when voclosporin treatment was added to mycophenolate and a low-dose ...
- ICU nurse with lupus is battling a need for own medicine and protective equipment amid coronavirus crisison March 30, 2020 at 12:56 pm
As a nurse with Lupus, Alicia Bligen is not only concerned about catching COVID-19, she's also worried about a shortage of hydroxychloroquine, a medicine she takes daily to function.
- Lupus, rheumatoid arthritis sufferers struggle to find needed drugson March 30, 2020 at 10:33 am
Groups representing lupus and rheumatoid arthritis sufferers are asking for immediate action from pharmacy boards to ensure access to drugs relied on for decades to control the diseases. The drugs, hy ...
- Trump calls it a COVID-19 fix. Now lupus patients can't get their drugon March 30, 2020 at 2:42 am
KANSAS CITY, Mo. — Before Aisha Kelley headed to the pharmacy last week, she heard from a fellow lupus patient that she might have trouble getting her prescription filled. Her medication, ...
- Northeast Ohio coronavirus drug hoarding hurting lupus, arthritis patientson March 29, 2020 at 5:03 pm
The desperate search for drugs, which may help fight the coronavirus, is now causing a growing shortage of a drug that is crucial for patients suffering from lupus and arthritis.
- Lupus patients having trouble getting drug named as possible treatment for COVID-19on March 29, 2020 at 5:26 am
Hydroxychloroquine and Chloroquine have been touted as possible treatments for COVID-19, and Lupus patients are having a harder time getting prescriptions filled.
- Demand for Lupus Drug Also Used to Treat COVID-19 Skyrocketson March 28, 2020 at 10:40 am
Now a San Diego, California woman who uses the medication to treat her lupus can’t get her prescription refilled. When Micaela Jimenez came to the pharmacy at the Kaiser Permanente in Rancho Bernardo, ...
- Low-dose 17α-ethinyl estradiol (EE) exposure exacerbates lupus renal disease and modulates immune responses to TLR7/9 agonistson March 28, 2020 at 5:26 am
Estrogens have been shown to regulate the immune system and modulate multiple autoimmune diseases. 17α-ethinyl estradiol (EE), a synthetic analog of 17β-estradiol, is prescribed ...
- Dawn of New Lupus Nephritis Treatment After AURORA Trialon March 27, 2020 at 1:47 pm
For patients with lupus nephritis, kidney response improves when voclosporin (Aurinia Pharmaceuticals) is added to mycophenolate and low-dose corticosteroids, results from the phase 3 AURORA trial ...
via Bing News